Welcome to our dedicated page for Mangoceuticals news (Ticker: MGRX), a resource for investors and traders seeking the latest updates and insights on Mangoceuticals stock.
Mangoceuticals, Inc. develops, markets and sells health and wellness products through a secure telemedicine platform under the MangoRx and PeachesRx brands. Company news commonly covers telehealth programs for erectile dysfunction, hair growth, hormone replacement therapy and weight management, including prescription access and fulfillment through pharmacy partners when medically appropriate.
Recurring updates also include product and intellectual-property developments such as MGX-0024, an antiviral animal feed and drinking water additive technology, as well as capital actions, platform operations and legal matters involving technology vendors. The company’s releases often connect its wellness brands, digital consultation model and eCommerce infrastructure to new treatment categories and operating initiatives.
Mangoceuticals, Inc. (NASDAQ:MGRX) has successfully closed its initial public offering of 1,250,000 shares at $4.00 per share, resulting in gross proceeds of $5,000,000. The offering included a 45-day option for underwriters to purchase an additional 187,500 shares. The funds will be allocated toward marketing, operational expenses related to its ED drug, 'Mango,' personnel hiring, software development, and general corporate purposes. The common stock began trading on Nasdaq on March 21, 2023. Boustead Securities, LLC was the sole managing underwriter. The offering was registered with the SEC, effective March 20, 2023.
Mangoceuticals, Inc. has announced its initial public offering (IPO) of 1,250,000 shares at $4.00 each, generating gross proceeds of $5,000,000. The shares will commence trading on Nasdaq under the ticker symbol MGRX on March 21, 2023, with the offering expected to close on March 23, 2023. The company plans to utilize the funds for marketing its ED drug, 'Mango,' hiring personnel, software development, and general corporate purposes. Boustead Securities, LLC is the sole managing underwriter. A 45-day overallotment option for an additional 187,500 shares is also granted to underwriters.